Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia
Phase 2 clinical trial to evaluate the combination of venetoclax, cytarabine and metformin in relapsed-refractory and induction ineligible acute myeloid leukemia.
Acute Myeloid Leukemia
DRUG: Venetoclax|DRUG: Cytarabine Injection|DRUG: Metformin
Overall Survival (OS), Overall survival is defined as the time from patient inclusion to the date of death, using Kaplan-Meier methodology., 12 months and 24 months
Composite Complete Response Rate (CCR), Percentage of participants with complete remission (CR) or complete remission with partial (CRh) or incomplete blood count recovery (CRi) at any time during the study as assessed by the investigator. Response was based on physical examination, bone marrow results and hematology values according to the revised guidelines by the 2022 European LeukemiaNet AML Diagnosis and Treatment Recommendations., 12 months and 24 months|Negative Measurable Residual Disease (MRD) Rate, Percentage of participants with CR, CRh or CRi with negative measurable residual disease (MRD) as assessed by the investigator, in accordance with ELN recommendations, defined as having less than 10-Â³ residual blasts per leukocyte measured in the bone marrow., 12 months and 24 months
Subjects will be included voluntarily after informed consent. Diagnosis of AML in accordance with the WHO classification and determination of inegibility to induction therapy or refractory or relapsed disease after initial treatment.